PacBio Q2 Revenues Down 31 Percent; Booked One Sequencer During Quarter | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences saw its second-quarter revenues fall 31 percent year over year, the company reported after the close of the market on Thursday, but the firm beat consensus Wall Street estimates on the top line and the bottom line.

For the three months ended June 30, PacBio took in $7.3 million in revenues, down from $10.6 million a year ago. Revenues beat analysts projections, however, which averaged $6.9 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.